Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Active-Pharmaceutical-Ingredients"

150 News Found

SMS Pharmaceuticals reports robust Q2FY24 operational performance
News | November 10, 2023

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore


Clariant launches new range of excipients to improve stability and solubility of APIs at CPHI Barcelona
News | October 19, 2023

Clariant launches new range of excipients to improve stability and solubility of APIs at CPHI Barcelona

New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral


Lupin enters into BTA with Lupin Manufacturing Solutions
News | October 17, 2023

Lupin enters into BTA with Lupin Manufacturing Solutions

Lupin enters into BTA with Lupin Manufacturing Solutions


ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
News | October 16, 2023

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy


Briefs: Granules India
Drug Approval | August 28, 2023

Briefs: Granules India

Granules India received approval from Brazilian Health Regulatory Agency ANVISA


Supriya Lifescience collaborates with Plasma Nutrition for protein technology
News | August 03, 2023

Supriya Lifescience collaborates with Plasma Nutrition for protein technology

The primary purpose of this collaboration is to bring the optimized protein into the Indian market


Teva Pharmaceuticals engages Honeywell to help reduce carbon impact
Sustainability | July 26, 2023

Teva Pharmaceuticals engages Honeywell to help reduce carbon impact

Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model


Evonik and Heraeus cooperate to expand the range of services for highly potent API
News | July 17, 2023

Evonik and Heraeus cooperate to expand the range of services for highly potent API

Evonik specializes in mid- to large-scale, later clinical phase HPAPIs